For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | - | 0 | - | - |
| Research and development | 3,521,576 | 3,507,906 | 2,601,122 | 2,292,040 |
| General and administrative | 653,066 | 538,047 | 681,210 | 437,011 |
| Total operating expenses | 4,174,642 | 4,045,953 | 3,282,332 | 2,729,051 |
| Loss from operations | -4,174,642 | -4,045,953 | -3,282,332 | -2,729,051 |
| Interest income | 22,797 | 20,675 | 23,970 | 60,338 |
| Net loss | -4,151,845 | -4,025,278 | -3,258,362 | -2,668,713 |
| Net loss per common share, basic | -0.3 | -0.3 | -0.25 | -0.2 |
| Net loss per common share, diluted | -0.3 | -0.3 | -0.25 | -0.2 |
| Weighted average common shares outstanding, basic | 13,641,384 | 13,370,983 | 13,171,555 | 13,142,457 |
| Weighted average common shares outstanding, diluted | 13,641,384 | 13,370,983 | 13,171,555 | 13,142,457 |
Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI)